There is currently no blood test for lung cancer diagnosis or prognosis. LUNGMARK has potential to be this test.

About

We have discovered a group of 6 molecules, known as microRNA biomarkers, circulating in the bloodstream and associated with the presence of the deadliest form of lung cancer (adenocarcinoma; the single biggest cancer killer in the world). These can be tested for using simple PCR methods. The Problem Lung adenocarcinoma is the biggest cancer killer. There is no blood test available for its diagnosis. Less than 80% are diagnosis a late stage when the tumour has spread. Around 20% of people diagnosed survive 1 year. There currently is no means of early diagnosis. The Opportunity LUNGMARK is available for licensing to a company who is keen to increase their exports with minimally-invasive cancer biomarkers. Alternatively, if you would like to continue research in this area, there are various support mechanisms and grants suitable for furthering the development of LUNGMARK in collaboration with Dr. O’Driscoll, Dr. Rani and Prof. O’Byrne (Consultant Oncologist/Lung Cancer Specialist) at Trinity College Dublin.  

Register for free for full unlimited access to all innovation profiles on LEO

  • Discover articles from some of the world’s brightest minds, or share your thoughts and add one yourself
  • Connect with like-minded individuals and forge valuable relationships and collaboration partners
  • Innovate together, promote your expertise, or showcase your innovations